Selection of a patient subgroup with advanced esophageal squamous carcinoma who could benefit from second-line chemotherapy

Oncology

Volumn 79, Issue 5-6, 2011, Pages 363-369

  Kim, Seung Tae ^a   Park, Kyong Hwa ^a   Oh, Sang Cheul ^a   Seo, Jae Hong ^a   Shin, Sang Won ^a   Kim, Jun Suk ^a   Kim, Yeul Hong ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Chemotherapy, second line; Esophageal squamous cell carcinoma; Prognostic model

Indexed keywords

BLEOMYCIN; CISPLATIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE; PLATINUM;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE SEVERITY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PATIENT SELECTION; PNEUMONIA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PATIENT SELECTION; PROGNOSIS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 79952840480     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000322498     Document Type: Article

References (27)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ: Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5-26.
2. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W, Minsky BD, Roth JA: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998; 339: 1979-1984. (Pubitemid 29024130)
3. Ajani J, Bekaii-Saab T, D'Amico TA, Fuchs C, Gibson MK, Goldberg M, Hayman JA, Ilson DH, Javle M, Kelley S, Kurtz RC, Locker GY, Meropol NJ, Minsky BD, Orringer MB, Osarogiagbon RU, Posey JA, Roth J, Sasson AR, Swisher SG, Wood DE, Yen Y: Esophageal cancer clinical practice guidelines. J Natl Compr Canc Netw 2006; 4: 328-347. (Pubitemid 44265354)
4. Holmes RS, Vaughan TL: Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol 2007; 17: 2-9. (Pubitemid 44918357)
5. Enzinger PC, Ilson DH, Kelsen DP: Chemotherapy in esophageal cancer. Semin Oncol 1999; 26: 12-20. (Pubitemid 29529532)
6. Hironaka S, Ohtsu A, Boku N, Muto M, NagashimaF, Saito H, Yoshida S, Nishimura M, Haruno M, Ishikura S, Ogino T, Yamamoto S, Ochiai A: Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with t(2-3)n(any) m(0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 2003; 57: 425-433. (Pubitemid 37040939)
7. Iizuka T, Kakegawa T, Ide H, Ando N, Watanabe H, Tanaka O, Takagi I, Isono K, Ishida K, Arimori M, et al: Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese esophageal oncology group trial. Jpn J Clin Oncol 1992; 22: 172-176.
8. Hayashi K, Ando N, Watanabe H, Ide H, Nagai K, Aoyama N, Takiyama W, Ishida K, Isono K, Makuuchi H, Imamura M, Shinoda M, Ikeuchi S, Kabuto T, Yamana H, Fukuda H: Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) trial (JCOG9407). Jpn J Clin Oncol 2001; 31: 419-423. (Pubitemid 33039748)
9. Williamson SK, McCoy SA, Gandara DR, Dakhil SR, Yost KJ, Paradelo JC, Atkins JN, Blanke CD, Abbruzzese JL: Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trial. Am J Clin Oncol 2006; 29: 116-122. (Pubitemid 44270947)
10. Polee MB, Kok TC, Siersema PD, Tilanus HW, Splinter TA, Stoter G, Van der Gaast A: Phase II study of the combination cisplatin, etoposide, 5-fluorouracil and folinic acid in patients with advanced squamous cell carcinoma of the esophagus. Anticancer Drugs 2001; 12: 513-517. (Pubitemid 32692595)
11. Lee J, Im YH, Cho EY, Hong YS, Lee HR, Kim HS, Kim MJ, Kim K, Kang WK, Park K, Shim YM: A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. Cancer Chemother Pharmacol 2008; 62: 77-84. (Pubitemid 351537848)
12. Lee S, Park YH, Kim KH, Cho EY, Ahn YC, Kim K, Shim YM, Ahn JS, Park K, Im YH: Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma. Br J Cancer;103: 845-851.
13. Heath EI, Urba S, Marshall J, Piantadosi S, Forastiere AA: Phase ii trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus. Invest New Drugs 2002; 20: 95-99. (Pubitemid 34251655)
14. Anderson SE, O'Reilly EM, Kelsen DP, Ilson DH: Phase II trial of 96-hour paclitaxel in previously treated patients with advanced esophageal cancer. Cancer Invest 2003; 21: 512-516. (Pubitemid 37169554)
15. Muro K, Hamaguchi T, Ohtsu A, Boku N, Chin K, Hyodo I, Fujita H, Takiyama W, Ohtsu T: A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 2004; 15: 955-959. (Pubitemid 39004353)
16. Conroy T, Etienne PL, Adenis A, Wagener DJ, Paillot B, Francois E, Bedenne L, Jacob JH, Seitz JF, Bleiberg H, Van Pottelsberghe C, Van Glabbeke M, Delgado FM, Merle S, Wils J: Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma: European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group. J Clin Oncol 1996; 14: 164-170.
17. Lorenzen S, Duyster J, Lersch C, von Delius S, Hennig M, Bredenkamp R, Peschel C, Lordick F: Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial. Br J Cancer 2005; 92: 2129-2133. (Pubitemid 40966246)
18. Lordick F, von Schilling C, Bernhard H, Hennig M, Bredenkamp R, Peschel C: Phase II trial of irinotecan plus docetaxel in cisplatin- pretreated relapsed or refractory oesophageal cancer. Br J Cancer 2003; 89: 630-633. (Pubitemid 37076164)
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
20. Bleiberg H, Conroy T, Paillot B, Lacave AJ, Blijham G, Jacob JH, Bedenne L, Namer M, De Besi P, Gay F, Collette L, Sahmoud T: Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 1997; 33: 1216-1220. (Pubitemid 27359638)
21. Spiridonidis CH, Laufman LR, Jones JJ, Gray DJ, Cho CC, Young DC: A phase II evaluation of high dose cisplatin and etoposide in patients with advanced esophageal adenocarcinoma. Cancer 1996; 78: 2070-2077. (Pubitemid 26367598)
22. Petrasch S, Welt A, Reinacher A, Graeven U, Konig M, Schmiegel W: Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. Br J Cancer 1998; 78: 511-514. (Pubitemid 28360641)
23. Ilson DH, Saltz L, Enzinger P, Huang Y, Kornblith A, Gollub M, O'Reilly E, Schwartz G, DeGroff J, Gonzalez G, Kelsen DP: Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 1999; 17: 3270-3275. (Pubitemid 29470662)
24. Enzinger PC, Mayer RJ: Esophageal cancer. N Engl J Med 2003; 349: 2241-2252. (Pubitemid 37485141)
25. Tanaka T, Fujita H, Sueyoshi S, Tanaka Y, Sasahara H, Mori N, Nagano T, Yamana H, Shirouzu K: Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience. Chemotherapy 2007; 53: 449-453. (Pubitemid 350085262)
26. Yamazaki K, Hironaka S, Boku N, Yasui H, Fukutomi A, Yoshino T, Onozawa Y, Hasuike N, Inui T, Yamaguchi Y, Ono H: A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum. Int J Clin Oncol 2008; 13: 150-155. (Pubitemid 351668173)
27. Jin J, Xu X, Wang F, Yan G, Liu J, Lu W, Li X, Tucker SJ, Zhong B, Cao Z, Wang D: Secondline combination chemotherapy with docetaxel and nedaplatin for cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma. J Thorac Oncol 2009; 4: 1017-1021.